Apr 10, 2019 / 03:20PM GMT
Alan Carr - Needham & Company, LLC, Research Division - Senior Analyst
All right. Good morning, everyone. I'm Alan Carr. I've got Tal Zaks with me from Moderna, and we're delighted you could be here with us this morning.
Tal Zaks - Moderna, Inc. - Chief Medical Officer
Thank you. It's great to be here.
Questions and Answers:
Alan Carr - Needham & Company, LLC, Research Division - Senior AnalystSo I want to go over -- we're going to cover a lot of topics. As I was just saying, there's a pretty broad investor base in Moderna, so I thought it makes sense to start off with some sort of big picture questions about mRNA and the technology and then go through some of the pipeline programs. But maybe we can just start off with some big picture thoughts on mRNA technology. Why is it different? And why has it been a challenge in the past to develop mRNA as a drug?
Tal Zaks - Moderna, Inc. - Chief Medical Officer
Thank you, Alan. Great to be here. So let me start with
Trustpilot
